182 related articles for article (PubMed ID: 37876963)
1. NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report.
Palmerini E; Frega G; Gambarotti M; Frisoni T; Cesari M; Bazzocchi A; Miceli M; Donati DM; Fanti S; Nanni C; Benini S; Longhi A; Paioli A; Marrari A; Hakim R; Righi A; Ibrahim T
Front Oncol; 2023; 13():1252359. PubMed ID: 37876963
[TBL] [Abstract][Full Text] [Related]
2. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract][Full Text] [Related]
3. Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report.
Lanman T; Hayden Gephart M; Bui N; Toland A; Nagpal S
Case Rep Oncol; 2021; 14(3):1841-1846. PubMed ID: 35111018
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy.
Recine F; De Vita A; Fausti V; Pieri F; Bongiovanni A; Franchini E; Casadei R; Falasconi MC; Oboldi D; Matteucci F; Pallotti MC; Mercatali L; Riva N; Gurrieri L; Vanni S; Liverani C; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Front Oncol; 2021; 11():740676. PubMed ID: 35070960
[TBL] [Abstract][Full Text] [Related]
5. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
[No Abstract] [Full Text] [Related]
6. Case report:
Lazzari C; Pecciarini L; Doglioni C; Pedica F; Gajate AMS; Bulotta A; Gregorc V; Cangi MG
Front Oncol; 2022; 12():1038774. PubMed ID: 36419889
[TBL] [Abstract][Full Text] [Related]
7. Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report.
Percy C; Schubert T; Galant C; Kirchgesner T; Mazzeo F
Clin Case Rep; 2021 Mar; 9(3):1694-1698. PubMed ID: 33768917
[TBL] [Abstract][Full Text] [Related]
8. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
[TBL] [Abstract][Full Text] [Related]
9. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
[TBL] [Abstract][Full Text] [Related]
10. A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma.
Bai C; Zhang L; Wang Y; You X; Ju Y; Sun T; Fan Z
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2933-2937. PubMed ID: 35933643
[TBL] [Abstract][Full Text] [Related]
11. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
Carlson JJ; Italiano A; Brose MS; Federman N; Lassen U; Kummar S; Sullivan SD
Am J Manag Care; 2022 Jan; 28(2 Suppl):S26-S32. PubMed ID: 35201681
[TBL] [Abstract][Full Text] [Related]
13. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.
Rabban JT; Devine WP; Sangoi AR; Poder L; Alvarez E; Davis JL; Rudzinski E; Garg K; Bean GR
Histopathology; 2020 Jul; 77(1):100-111. PubMed ID: 31971278
[TBL] [Abstract][Full Text] [Related]
14. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
Wu WC; Chen MH
Front Oncol; 2022; 12():1031396. PubMed ID: 36703785
[TBL] [Abstract][Full Text] [Related]
15. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
[TBL] [Abstract][Full Text] [Related]
16. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
[TBL] [Abstract][Full Text] [Related]
17. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS
Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570
[TBL] [Abstract][Full Text] [Related]
18. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
[TBL] [Abstract][Full Text] [Related]
19. Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion.
Shepherd DJ; Miller TE; Forst DA; Jones P; Nardi V; Martinez-Lage M; Stemmer-Rachamimov A; Gonzalez RG; Iafrate AJ; Ritterhouse LL
Oncologist; 2021 Nov; 26(11):919-924. PubMed ID: 34041811
[TBL] [Abstract][Full Text] [Related]
20. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
